Skip to content
‹ Back to IndustriesHealthcare

Mitigating the Spread of Hospital-Acquired Infections

During the global spread of the novel coronavirus, the ensuing COVID-19 pandemic and, now, efforts to engage in reopening, much has been said about strategies aimed at helping control infection in our daily lives. However, what about in the very facilities treating not only patients with COVID-19, but those with other conditions? Hospital-acquired infections, those…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

During the global spread of the novel coronavirus, the ensuing COVID-19 pandemic and, now, efforts to engage in reopening, much has been said about strategies aimed at helping control infection in our daily lives.

However, what about in the very facilities treating not only patients with COVID-19, but those with other conditions?

Hospital-acquired infections, those acquired in the hospital or place of treatment as opposed to prior to arriving at those facilities, can throw a major wrench in practices’ and hospitals’ ability to effectively care for patients.

Vioguard Vice President of Sales and Marketing, Mark Beeston, joined host Daniel Litwin to outline the company’s mission – improving infection control and helping curtail hospital-acquired infections – and how it goes about achieving those goals.

“[COVID-19] heightened awareness in the healthcare space,” Beeston said. “There were processes in place, already, but those processes have now been enhanced. You’re seeing more diligence in areas that are really hypersensitive.”

This heightened diligence has particularly affected places like newborn ICUs and operating rooms, and even families of patients are being more thoroughly screened and sanitized. It’s also increased attention on aspects of exposure that might have previously been overlooked, such as visitor cellphones.

Established in 2008, Vioguard develops solutions that utilize ultraviolet light to aid in sanitization efforts, working to provide effective infection control measures that don’t interfere with productivity or accuracy.

Litwin and Beeston explored how and why healthcare professionals might spread infection, the current state of prevention, and immediate and long-term strategies for avoiding hospital-acquired infections.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in Q3 2026 and raised 2026 revenue guidance to $1.04-$1.05 billion. Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a minimal residual disease assay, is targeted to launch before year-end.

  • 01Caris said higher operating expenses were driven primarily by headcount-related costs, research and development investment and marketing.
  • 02Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
  • 03Caris reaffirms its guidance for clinical therapy selection volume growth of approximately 20%.

Nov 8, 2026

Denials get a queue, underpayments just look like paid claims

Denials get a queue, underpayments just look like paid claims

Underpayments in healthcare revenue cycle operations lack the visibility of denied claims because they don't trigger alerts or queue workflows. Without dedicated ownership and line-level verification against contract terms, paid claims that fall short of their contractual amount pass through undetected.

  • 01Denial workflows activate on rejection events, but underpayments produce no event, leaving paid claims unverified by default.
  • 02The speaker says many provider groups lack line-level contract intelligence to check each paid line against the applicable terms.
  • 03Payment received and payment checked are separate tasks: one verifies acceptance, the other verifies correctness—and the second often has no assigned owner.

Nov 6, 2026

A zero-paid claim line is not automatically an underpayment

A zero-paid claim line is not automatically an underpayment

A zero payment on a claim line isn't automatically an underpayment; contract terms, particularly packaging rules, determine whether zero is correct. Chasing unsupported findings damages credibility with payers and weakens the position of legitimate disputes, so revenue cycle teams must verify the full contract terms and effective dates before treating any payment difference as a finding.

  • 01When a contract packages add-ons into the primary procedure, the add-on line may legitimately show zero payment because it is folded into the primary procedure reimbursement.
  • 02Pursuing payment differences that lack contract support burns credibility with payers and can weaken the team’s position on later disputes, including valid ones.
  • 03Always verify the complete contract terms, fee schedules, carve-outs, amendments, and the specific version in effect on the date of service before treating a payment variance as a recoverable underpayment.

Nov 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512